List of Excipients in Branded Drug TRAVOPROST OPHTHALMIC SOLUTON

« Back to Dashboard

Generic Drugs Containing TRAVOPROST OPHTHALMIC SOLUTON

Company	Ingredient	NDC	Excipient
Sagent Pharmaceuticals	travoprost	25021-002	BORIC ACID
Sagent Pharmaceuticals	travoprost	25021-002	HYDROCHLORIC ACID
Sagent Pharmaceuticals	travoprost	25021-002	POLYOXYL 40 HYDROGENATED CASTOR OIL
Sagent Pharmaceuticals	travoprost	25021-002	PROPYLENE GLYCOL
Sagent Pharmaceuticals	travoprost	25021-002	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in TRAVOPROST OPHTHALMIC SOLUTON?

# Of NDCs	Excipient
1	BORIC ACID
1	HYDROCHLORIC ACID
1	POLYOXYL 40 HYDROGENATED CASTOR OIL
1	PROPYLENE GLYCOL
1	SODIUM HYDROXIDE

Travoprost Ophthalmic Solution Excipient Strategy and Commercial Opportunities

Last updated: October 8, 2026

Travoprost ophthalmic solution is a mature prostaglandin analogue product with established efficacy, broad generic availability, and limited composition-of-matter exclusivity. The strongest commercial opportunities are in preservative-free multidose delivery, improved ocular tolerability, reduced dosing burden, device compatibility, and differentiated formulations for chronic glaucoma therapy.

Travoprost is typically supplied as a 0.004% ophthalmic solution for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Originator products include Travatan and Travatan Z, commercialized by Alcon. Generic products compete primarily on price and supply reliability. Excipient innovation, rather than travoprost itself, is the principal route to product differentiation.

What is the FDA status of travoprost ophthalmic solution?

Travoprost ophthalmic solution is an FDA-approved prescription drug for lowering intraocular pressure. It is a prostaglandin F2α analogue prodrug that is hydrolyzed in the eye to active travoprost acid.

Product category	Typical strength	Primary use	Commercial status
Travatan	0.004%	Open-angle glaucoma and ocular hypertension	Originator product
Travatan Z	0.004%	Open-angle glaucoma and ocular hypertension	Preservative-system differentiated originator
Generic travoprost ophthalmic solution	0.004%	Same approved indications	Abbreviated New Drug Application products
Combination products	Varies	Glaucoma requiring multi-agent treatment	Limited relevance to excipient-only strategies

The FDA-approved labeling identifies travoprost ophthalmic solution as a topical ocular product administered once daily, generally in the evening. The products are not interchangeable solely because they contain the same active ingredient. Preservative system, vehicle composition, container closure, and approved labeling can differ materially across products (FDA, 2024a; DailyMed, 2024a).

What excipients are used in travoprost ophthalmic solution?

Travoprost formulations use excipients to solubilize the lipophilic active ingredient, maintain pH and tonicity, control degradation, preserve multidose containers, and support ocular tolerability.

Common excipient functions

Excipient class	Typical function	Commercial relevance
Purified water	Vehicle	Required for aqueous ophthalmic delivery
Buffering agents	pH control	Affects stability, comfort, and preservative performance
Sodium chloride	Tonicity adjustment	Supports ocular comfort
Boric acid or borate salts	Buffering and tonicity	Used in established prostaglandin formulations
Propylene glycol	Solubilization and humectancy	Can improve formulation robustness but may affect comfort
Sorbitol	Tonicity and osmolality control	Supports a non-BAK preservative system
Zinc chloride	Preservative-system component and formulation aid	Associated with the sofZia-type approach
Tromethamine	Buffering and pH adjustment	Supports pH control
Benzalkonium chloride	Antimicrobial preservative	Effective and inexpensive, but creates chronic-use tolerability concerns
Polyquaternium-1	Preservative	Alternative to benzalkonium chloride in some ophthalmic products
Sodium hydroxide or hydrochloric acid	pH adjustment	Used during final formulation control

Travatan Z uses Alcon's sofZia preservative system, which is based on an ionic preservative approach rather than benzalkonium chloride. The labeled inactive ingredients include boric acid, propylene glycol, sorbitol, zinc chloride, tromethamine, and water, with pH adjustment as needed (DailyMed, 2024b).

The precise excipient balance affects more than shelf life. It influences corneal epithelial exposure, conjunctival irritation, bottle compatibility, drop size, chemical stability, and the commercial positioning of the product.

How does the Travatan Z excipient strategy compare with generic travoprost?

Travatan Z's principal differentiation is the preservative system. Many generic travoprost products use benzalkonium chloride, while Travatan Z uses a sofZia-type system.

Attribute	BAK-containing travoprost	SofZia-type travoprost	Preservative-free travoprost
Manufacturing complexity	Lower	Moderate	Higher
Ingredient cost	Generally lower	Moderate	Higher
Multidose preservation	Established	Established	Requires specialized container or packaging
Chronic ocular tolerability	Potential concern with long-term exposure	Positioned as an alternative	Strongest differentiation potential
Regulatory precedent	Extensive	Established in originator product	Requires robust container-closure data
Price competition	High	Moderate	Potentially lower competition
Commercial target	Broad generic market	Branded or premium generic	Ocular-surface-sensitive patients and specialty channels

Benzalkonium chloride remains attractive because it is inexpensive, widely understood by regulators, and compatible with conventional multidose bottles. Its limitation is cumulative ocular-surface exposure in chronic therapy. Glaucoma patients often use treatment for years and may receive multiple topical medications, increasing the commercial value of preservative reduction.

What formulation patents protect travoprost ophthalmic solution?

Travoprost's original active-ingredient and formulation patent estate is mature. The principal commercial barriers have shifted from basic travoprost composition claims to formulation details, preservative systems, containers, manufacturing controls, and regulatory exclusivity.

Potentially relevant patent categories include:

1. Travoprost and prostaglandin analogue compositions.
2. Aqueous ophthalmic solutions containing travoprost.
3. Preservative systems, including non-BAK systems.
4. pH, tonicity, solubilization, and buffering combinations.
5. Multidose dispensing containers.
6. Sterile manufacturing and fill-finish processes.
7. Combination glaucoma products.
8. Methods of reducing intraocular pressure.

The FDA Orange Book remains the controlling source for listed patents and regulatory exclusivity associated with approved products. Travoprost generic approvals demonstrate that core market barriers have largely expired or become nonblocking for conventional 0.004% solutions. A new formulation may still obtain patent protection if it has a non-obvious excipient combination, improved stability, reduced degradation, a novel delivery system, or clinically demonstrated tolerability benefits (FDA, 2024b).

A formulation patent is commercially stronger when it protects a product attribute that a competitor cannot easily design around. Broad claims covering "travoprost plus ophthalmically acceptable excipients" are generally vulnerable to invalidity and design-around arguments. Narrower claims tied to defined preservative concentrations, pH ranges, osmolality, container materials, or stability thresholds may be more defensible but provide less blocking scope.

When does travoprost lose exclusivity?

Travoprost has already lost the practical exclusivity associated with its original branded product. Generic travoprost ophthalmic solutions are commercially available, and the market is subject to abbreviated regulatory pathways rather than new-drug exclusivity for the active ingredient.

The relevant commercial distinction is between:

• Core travoprost exclusivity, which is mature.
• Product-specific formulation patents, which may vary by product.
• Device and container patents, which may create narrower barriers.
• Regulatory exclusivity for a newly approved differentiated product.
• Patent-term restoration or pediatric exclusivity, if applicable to a specific approval.

A new preservative-free or device-enabled travoprost product would need its own approval strategy. It could be submitted as a new drug product, a supplement to an existing application, or potentially through an abbreviated pathway if the formulation and delivery system satisfy FDA sameness requirements. The pathway depends on the reference product, inactive-ingredient differences, dosage form, container, and clinical evidence package.

What preservative-free opportunities exist for travoprost?

Preservative-free travoprost is the clearest formulation opportunity for premium positioning.

Single-dose unit-dose packaging

Unit-dose vials eliminate the need for a chemical preservative. The disadvantages are higher packaging costs, greater material consumption, more complicated patient handling, and potential adherence problems if the product is difficult to open or carry.

Commercial targets include:

• Patients with dry eye disease.
• Patients with corneal epithelial disease.
• Patients using multiple preserved ophthalmic medicines.
• Patients with documented benzalkonium chloride intolerance.
• Postoperative and specialty ophthalmology channels.

Preservative-free multidose bottles

A preservative-free multidose bottle uses a one-way valve, airless architecture, filter, or another microbial-control mechanism. This approach may produce a stronger product profile than unit-dose packaging because it improves portability and reduces waste.

The key development requirements are:

• Container-closure integrity.
• Microbial ingress resistance.
• Dose uniformity through bottle life.
• Priming and re-priming performance.
• Drop-size control.
• Compatibility with travoprost and vehicle components.
• Extractables and leachables control.
• Stability after repeated opening and use.

A preservative-free multidose product can support premium pricing, but the container is part of the intellectual property strategy. A formulation without corresponding device protection may be vulnerable to rapid copying.

What excipient strategies can improve commercial differentiation?

Reduce benzalkonium chloride exposure

The most direct strategy is to replace BAK with a non-BAK preservative system or remove the preservative entirely. SofZia provides regulatory and commercial precedent for a non-BAK travoprost product.

A non-BAK system must demonstrate adequate antimicrobial effectiveness without creating unacceptable ocular irritation. The development risk is higher than for a conventional BAK formulation because preservative performance depends on the complete formulation, container, pH, ionic strength, and use pattern.

Optimize solubilization

Travoprost is lipophilic. Propylene glycol and related cosolvent strategies can support solubilization, but excessive cosolvent concentration may affect comfort or epithelial tolerability. Commercially attractive formulations would maintain travoprost concentration while reducing irritant excipients and minimizing precipitation after storage.

Control pH and osmolality

A formulation close to physiologic tonicity and within a tolerable pH range can improve patient acceptance. The optimal values must be balanced against chemical stability and preservative activity. A patentable formulation may require a defined pH range, osmolality window, buffer ratio, and stability outcome rather than a generic claim to pH adjustment.

Improve drop-size consistency

A smaller, more consistent drop can reduce overflow, systemic absorption, and product waste. The commercial opportunity sits partly in the dispensing system, but excipient viscosity and interfacial properties can influence dose delivery. Any change must preserve bioavailability and avoid increasing administration difficulty.

Develop a low-irritation vehicle

Humectants and tonicity agents can be selected to reduce ocular-surface stress. Sorbitol, glycerol, polyethylene glycol derivatives, and related excipient systems may support comfort, but they require compatibility testing with the active ingredient and container.

What manufacturing and intellectual-property barriers affect travoprost?

The active ingredient is not the primary manufacturing barrier. The commercial barriers are sterile ophthalmic production, impurity control, aseptic filling, container performance, and reproducible preservative effectiveness.

Manufacturing barriers

• Low-dose uniformity at 0.004%.
• Control of degradation and oxidation.
• Sterile filtration or aseptic processing.
• Preservative effectiveness testing.
• Container-closure integrity.
• Compatibility with low-extractables packaging.
• Drop-size and fill-volume consistency.
• Supply reliability for specialized bottles or unit-dose components.

IP barriers

• Non-BAK preservative compositions.
• Preservative-free multidose dispensing systems.
• Bottle valves and airless packages.
• Specific pH and buffer systems.
• Stability claims linked to excipient ratios.
• Combination products with other glaucoma agents.
• Manufacturing processes that reduce impurities or improve shelf life.

A company can create a stronger estate by filing composition, container, method-of-use, and manufacturing applications together. The estate should include independent claims directed to the formulation and separate claims directed to the device. This structure limits the ability of a competitor to avoid infringement by changing only the vehicle or only the bottle.

Which companies are competing in travoprost?

The competitive market includes originator and generic manufacturers. Alcon retains the strongest branded association through Travatan and Travatan Z. Generic competition includes manufacturers that market 0.004% travoprost ophthalmic solution under abbreviated approvals.

The principal competitive segments are:

Segment	Competitive basis	Margin outlook
Conventional generic travoprost	Price, supply, wholesaler access	Low
Branded non-BAK travoprost	Tolerability and physician preference	Moderate
Preservative-free travoprost	Ocular-surface positioning	Potentially high
Travoprost combinations	Convenience and adherence	Moderate to high
Device-enabled product	Drop accuracy and usability	Potentially high
Contract manufacturing	Sterile capacity and quality systems	Service-margin opportunity

A new entrant is unlikely to win through active-ingredient differentiation. It would need a defensible formulation, a better container, a meaningful tolerability claim, or channel-specific commercial access.

What Paragraph IV and litigation risks apply to travoprost?

Paragraph IV risk is most relevant when a company seeks approval for a product that may implicate listed patents covering a branded formulation, preservative system, delivery device, or method of use.

For a conventional generic travoprost solution, the main risks are usually:

• Listed formulation patents.
• Orange Book-listed container or delivery patents.
• Certification disputes over inactive ingredients.
• Product-specific litigation concerning non-BAK formulations.
• Patent claims covering combination therapy or dosing methods.

A Paragraph IV certification can trigger a 30-month stay if the relevant statutory conditions are met. The commercial impact depends on the patent's expiration date, claim scope, litigation venue, settlement terms, and whether the proposed product can be redesigned without losing regulatory equivalence (FDA, 2024b; 21 U.S.C. § 355).

No commercial strategy should assume that the absence of a core active-ingredient patent eliminates litigation risk. Formulation and device patents can remain relevant even after generic entry.

What licensing opportunities exist for travoprost excipients and devices?

Licensing opportunities are more attractive in delivery technology than in the travoprost molecule.

Potential licensing targets include:

• Preservative-free multidose bottles.
• Airless ophthalmic pumps.
• Low-drop-volume dispensers.
• Non-BAK preservative systems.
• Ophthalmic solubilization platforms.
• Sterile unit-dose fill-finish capacity.
• Combination-product technologies.
• Regional rights for emerging-market glaucoma products.

An excipient supplier could pursue a formulation-development license with a generic manufacturer, while a device company could license its container platform to multiple ophthalmic products. The strongest deal structure would tie royalties to approved products and include rights to improvements, formulation changes, and regional regulatory filings.

How strong is the patent estate for a new travoprost formulation?

A new travoprost formulation can have moderate patent strength if it combines a differentiated excipient system with a measurable product benefit.

Development concept	Patent strength	Regulatory complexity	Commercial potential
Simple BAK reformulation	Low	Low to moderate	Low
Non-BAK preserved solution	Moderate	Moderate	Moderate
Preservative-free unit dose	Moderate	Moderate	Moderate
Preservative-free multidose	High if device claims are strong	High	High
Improved drop-size device	Moderate to high	Moderate to high	High
Travoprost combination product	Moderate	High	Moderate to high
New vehicle with tolerability data	Moderate	Moderate to high	Moderate
Novel sustained-release delivery	High	High	High, but technically demanding

Patent value increases when the formulation produces unexpected stability, reduced ocular-surface toxicity, improved adherence, or superior administration performance. Without clinical or comparative evidence, excipient changes may be difficult to monetize.

What generic launch scenarios exist for travoprost?

Low-cost conventional generic

This is the fastest and least differentiated route. The product uses a conventional bottle and established preservative system. It faces intense price competition and limited physician switching.

Premium non-BAK generic

This product targets patients who cannot tolerate BAK or who receive multiple chronic ophthalmic therapies. The commercial case depends on payer coverage and physician recognition of ocular-surface benefits.

Preservative-free specialty product

This product can command a higher price and support ophthalmology-focused distribution. Packaging cost and adherence are the principal risks.

Device-led product

A device with controlled drop size, easier handling, or preservative-free multidose delivery can support patent protection and product differentiation. The regulatory package is more complex because the container and delivery system become central to product performance.

Key Takeaways

• Travoprost 0.004% is a mature generic market with limited opportunity in the active ingredient itself.
• Excipient strategy is most valuable when it supports preservative reduction, ocular-surface tolerability, stability, or dose delivery.
• Travatan Z demonstrates the commercial precedent for a non-BAK travoprost preservative system.
• Preservative-free multidose delivery is the strongest potential premium opportunity.
• A defensible product should combine formulation claims with container, manufacturing, and method-of-use claims.
• Conventional BAK-containing generic products face low margins and limited differentiation.
• The main regulatory and manufacturing risks are microbial control, sterility, container compatibility, low-dose uniformity, and drop-size consistency.
• Paragraph IV exposure depends on product-specific Orange Book listings rather than the age of the travoprost molecule alone.
• Device licensing and specialty ophthalmology partnerships may offer more value than conventional excipient licensing.
• Commercial success requires demonstrated tolerability or usability benefits, not merely a different inactive-ingredient list.

FAQs

Is travoprost ophthalmic solution preservative-free?

Most conventional generic travoprost products contain a preservative. Travatan Z uses a non-BAK sofZia-type preservative system. Fully preservative-free products require unit-dose packaging or a validated preservative-free multidose container.

Which excipient is most important in Travatan Z?

The commercial differentiator is the sofZia preservative system, which includes zinc chloride with borate, sorbitol, propylene glycol, tromethamine, and related formulation components. Its value lies in replacing benzalkonium chloride while maintaining multidose preservation.

Can a generic travoprost product use different excipients from the reference product?

Yes, an abbreviated product may use different inactive ingredients if it satisfies FDA requirements for safety, efficacy, pharmaceutical equivalence, bioequivalence, and inactive-ingredient suitability. Ophthalmic products face specific requirements for sterility and local tolerability.

Is a new travoprost bottle patentable?

A bottle may be patentable if it has a novel dispensing architecture, microbial-control mechanism, dose-delivery performance, or compatibility profile. A routine bottle substitution generally provides weak patent protection.

Is travoprost a biosimilar opportunity?

No. Travoprost is a small-molecule drug, not a biologic. The relevant competitive pathways are generic drug approvals, new drug applications, formulation changes, and combination-product strategies rather than biosimilar applications.

References

1. DailyMed. (2024a). Travoprost ophthalmic solution, 0.004%: Prescribing information. U.S. National Library of Medicine.

2. DailyMed. (2024b). Travatan Z: Travoprost ophthalmic solution, 0.004%: Prescribing information. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024a). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (2024c). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/

6. U.S. Code, 21 U.S.C. § 355. New drugs.